- Home
- DXCM vs LII Comparison
DXCM vs LII Comparison
Compare DXCM & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | LII |
|---|---|---|
| Founded | 1999 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5B | 19.5B |
| IPO Year | 2005 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DXCM | LII |
|---|---|---|
| Price | $62.99 | $469.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 21 | 12 |
| Target Price | $85.33 | ★ $582.82 |
| AVG Volume (30 Days) | ★ 3.4M | 390.3K |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.12% |
| EPS Growth | ★ 47.18 | 1.11 |
| EPS | 2.09 | ★ 22.79 |
| Revenue | N/A | ★ $5,195,300,000.00 |
| Revenue This Year | $14.48 | $6.89 |
| Revenue Next Year | $12.39 | $5.74 |
| P/E Ratio | $30.05 | ★ $20.35 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.11 | $434.06 |
| 52 Week High | $89.07 | $689.44 |
Technical Indicators
Market Signals| Indicator | DXCM | LII |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 42.73 |
| Support Level | $54.11 | $443.19 |
| Resistance Level | $69.18 | $571.67 |
| Average True Range (ATR) | 1.99 | 16.80 |
| MACD | -0.37 | -1.01 |
| Stochastic Oscillator | 20.59 | 63.99 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About LII Lennox International Inc.
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.